Lexaria Bioscience (LEXX) Depreciation & Amortization (CF) (2010 - 2025)
Lexaria Bioscience (LEXX) posted Depreciation & Amortization (CF) of -$66427.0 for Q3 2025, down 314.59% sequentially from $30955.0 in Q2 2025, and down 505.78% YoY from $16370.0 in Q3 2024.
Lexaria Bioscience (LEXX) Depreciation & Amortization (CF) (2010 - 2025) Analysis & Trends
Lexaria Bioscience has reported Depreciation & Amortization (CF) for 13 years, with the latest figure at -$66427.0 in Q3 2025.
- Quarterly Depreciation & Amortization (CF) fell 505.78% year-over-year to -$66427.0 in Q3 2025, while the trailing twelve-month figure through May 2026 was -$66427.0 (down 180.23% YoY) and the FY2024 annual result came in at $76153.0, down 47.62% from the prior year.
- Depreciation & Amortization (CF) eased to -$66427.0 in Q3 2025 per LEXX's latest filing, from $30955.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $70928.0 in Q3 2023 and troughed at -$66427.0 in Q3 2025.
- A 5-year average of $21476.7 and a median of $25010.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) jumped 186.79% in 2023, then slumped 505.78% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $27930.0 in 2021, then decreased by 11.46% to $24730.0 in 2022, then climbed by 16.37% to $28778.0 in 2023, then grew by 15.35% to $33195.0 in 2024, then sank by 300.11% to -$66427.0 in 2025.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered -$66427.0, $30955.0, and $2277.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 19,208.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Aug 31, 2025 | -66,427.00 |
| Aug 31, 2025 | -66,427.00 |
| May 31, 2025 | 30,955.00 |
| May 31, 2025 | 30,955.00 |
| Feb 28, 2025 | 2,277.00 |
| Feb 28, 2025 | 2,277.00 |
| Nov 30, 2024 | 33,195.00 |
| Nov 30, 2024 | 33,195.00 |
| Aug 31, 2024 | 16,370.00 |
| Aug 31, 2024 | 16,370.00 |
| May 31, 2024 | 15,074.00 |
| May 31, 2024 | 15,074.00 |
| Feb 29, 2024 | 15,931.00 |
| Feb 29, 2024 | 15,931.00 |
| Nov 30, 2023 | 28,778.00 |
| Nov 30, 2023 | 28,778.00 |
| Aug 31, 2023 | 70,928.00 |
| Aug 31, 2023 | 70,928.00 |
| May 31, 2023 | 25,010.00 |
| May 31, 2023 | 25,010.00 |